RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Clinical trials for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS explained in plain language.
Never miss a new study
Get alerted when new RESPIRATORY SYNCYTIAL VIRUS INFECTIONS trials appear
Sign up with your email to follow new studies for RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
RSV booster study aims to keep seniors safe for five seasons
⭐️ VACCINE ⭐️ OngoingThis study looks at the best timing for a booster shot of the RSV vaccine in adults aged 60 and older. It will follow over 10,000 participants for up to 5 years to see how long protection lasts and whether a second dose is needed. The goal is to help prevent serious RSV infection…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:37 UTC
-
New RSV vaccine trial aims to protect vulnerable transplant recipients
⭐️ VACCINE ⭐️ OngoingThis phase 3 trial is testing a non-live, adjuvanted RSV vaccine (Arexvy) in 100 adults who have received a lung or stem cell transplant. The goal is to see if the vaccine is safe and helps their immune system fight RSV, a common virus that can be dangerous for them. Participants…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: University Health Network, Toronto • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:28 UTC
-
New mRNA vaccine takes aim at RSV in early human trial
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing a new mRNA vaccine called IN006 that targets respiratory syncytial virus (RSV). About 240 healthy adults aged 18 and older will receive either the vaccine or a placebo. The main goal is to check if the vaccine is safe and triggers an immune respo…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: Shenzhen Shenxin Biotechnology Co., Ltd • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:03 UTC
-
New RSV vaccine shows promise for seniors in major trial
⭐️ VACCINE ⭐️ OngoingThis study tests an experimental RSV vaccine in adults aged 60 and older. The goal is to see how well the vaccine triggers the immune system, how safe it is, and how long protection lasts—up to 5 years. About 1,720 participants will receive one or more doses of the vaccine at dif…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 11:03 UTC
-
New mRNA vaccine targets RSV in first human trial
⭐️ VACCINE ⭐️ OngoingThis early-stage trial is testing several doses of an experimental mRNA vaccine against RSV in 213 healthy adults aged 18-45. The goal is to check the vaccine's safety and how well it triggers an immune response. Participants receive two shots, and researchers monitor for side ef…
Matched conditions: RESPIRATORY SYNCYTIAL VIRUS INFECTIONS
Phase: PHASE1 • Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 26, 2026 15:03 UTC